1997 smiled on drug approvals, sales and prospects
Article Abstract:
The pharmaceutical industry's strong performance in 1997 is expected to continue into 1998, with predictions setting sales growth at 13% and totalling $81.3 billion. In 1997, sales rose 12%, 39 new drugs were approved and Congress renewed the user fees program, which helps defray Food and Drug Administration review costs. The mean drug approval period was also reduced to a record low of 16.2 months.
Publication Name: American Medical News
Subject: Health
ISSN: 0001-1843
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Tertiary center monitors rural patients via phone line
Article Abstract:
Cardiac patients in Utah's rural Allen Memorial hospital are being monitored in real-time at a tertiary hospital 250 miles away. The system uses a high-capacity telephone line to provide live data. Allen Memorial was able to retain patients who otherwise would have been transferred, saving the hospital around $85,000. Hospital officials hope the system will attract more physicians to the area.
Publication Name: American Medical News
Subject: Health
ISSN: 0001-1843
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Carbamazepine. The role of EEGs in the treatment and prognosis of epilepsy. The importance of brand continuity in epilepsy drugs
- Abstracts: Observational studies of drug safety--Aprotinin and the absence of transparency. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
- Abstracts: Diversity in medicine. Erythropoietin, the FDA, and oncology. The age of teleradiology
- Abstracts: Taking aim at handgun violence. New focus placed on von Willebrand disease
- Abstracts: Medical genetics. The Multifaceted Challenges of Proteus Syndrome. Diagnosis of X-linked adrenal hypoplasia congenita by mutation analysis of the DAX1 gene